Chen Mao, Ya-Fang Huang, Zu-Yao Yang, Da-Yong Zheng, Jin-Zhang Chen and Jin-Ling Tang KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer Cancer 119
Article first published online: 12 SEP 2012 | DOI: 10.1002/cncr.27804
Patients with metastatic colorectal cancer who have the v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS) p.G13D mutation (an amino acid substitution at position 13 in KRAS from a glycine to an aspartic acid) appear to benefit more from cetuximab than patients who have KRAS codon 12 mutations. Whether or not patients with metastatic colorectal cancer who have the p.G13D mutation should be excluded from cetuximab treatment needs to be reconsidered.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field
Choose captcha format: Image or Audio. Click here if you need help.